NVO and VKTX face rising competition and setbacks as investors weigh scale, pipelines and execution risks in the crowded ...

Novo Nordisk A/S is rated a Buy with solid long-term prospects, and the stock appears undervalued. Learn more about NVO stock ...

Merck's rebound has already started. The pharmaceutical giant performed well toward the end of 2025. But there could be even ...

Novo Nordisk A/S Q3 costs, Q4 savings, and oral Wegovy launch drive EPS upside. Click for this NVO stock update and earnings preview.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects healthy upside for Novo Nordisk stock through ...

Novo Nordisk AS was sued in federal court Friday with allegations that it monopolized the blockbuster weight loss medication Victoza through an illegal deal with a competitor to delay the generic, ...

DCGI approval to Sun Pharma comes amid an ongoing patent dispute with Novo Nordisk in the Delhi High Court. The case relates ...

Are GLP-1 drugs prescribed for weight loss becoming too outsized a line item for continued coverage through the state ...

Monthly injections, once-daily pills, and even lifelong gene therapies could soon become options for people looking to lose ...

EMVision Medical Devices and Clever Culture Systems are among ASX healthcare companies reporting milestones reached in ...

My top 10 things to watch Tuesday, Jan. 27 1. The S & P 500 was headed for a slightly higher open this morning ahead of Big Tech earnings tomorrow evening (Meta Platforms and Microsoft ) and Thursday ...

This summary highlights significant health news, including links of infant botulism to ByHeart's formula, investigations on ...